Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Laurus Labs. ImmunoACT announces the approval of India’s first CAR-T cell therapy, NexCAR19 (actalycabtagene autoleucel), for the treatment of r/r B-cell lymphomas and leukemia from the Central Drugs Standard Control Organization (CDSCO) [media release]. 13 Oct 2023. https://www.lauruslabs.com/.
2. Denlinger N, Bond D, Jaglowski S. CAR T-cell therapy for B-cell lymphoma. Curr Probl Cancer. 2022;46(1):100826.
3. Immunoadoptive Cell Therapy Pvt Ltd. Actalycabtagene autoleucel (NexCAR19): Indian prescribing information. Mumbai: Immunoadoptive Cell Therapy Pvt Ltd; 2023.
4. Kumar Suvvari T, Suresh V, Patel K, et al. CAR-T cell therapy in India: challenges and opportunities for advancement. Transfus Clin Biol. 2023;30(4):373–5.
5. Dwivedi A, Karulkar A, Ghosh S, et al. Robust antitumor activity and low cytokine production by novel humanized anti-CD19 CAR T cells. Mol Cancer Ther. 2021;20(5):846–58.